Skip to main content

Plasma Biomarkers of Alzheimer Neuropathy Linked to Dementia Risk

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 1, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Aug. 1, 2024 -- Plasma biomarkers of Alzheimer disease (AD) neuropathy increase with age and are associated with known dementia risk factors, according to a study published online July 28 in the Journal of the American Medical Association to coincide with the Alzheimer's Association International Conference, held from July 28 to Aug. 1 in Philadelphia.

Yifei Lu, Ph.D., from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, and colleagues examined temporal plasma biomarker changes and their association with all-cause dementia among 1,525 participants from the U.S.-based Atherosclerosis Risk in Communities study. Plasma biomarkers were measured using stored specimens collected in midlife (mean age, 58.3 years) and late life (mean age, 76.0 years); participants were followed until a mean age of 80.7 years. The associations of biomarkers with incident all-cause dementia were assessed in a subgroup of 1,339 individuals.

Of the 1,525 participants, 16.5 percent developed dementia. The researchers found that from midlife to late life, there was a decreasing ratio of amyloid-β 42 to amyloid-β 40 (Aβ42:Aβ40) and increasing phosphorylated tau at threonine 181 (p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein; more rapid changes in biomarkers were seen for participants harboring the apolipoprotein E epsilon 4 allele. Long-term associations were seen for AD-specific biomarkers in midlife with late-life dementia (hazard ratio per standard deviation [SD] lower Aβ42:Aβ40 ratio, 1.11; per SD higher p-tau181, 1.15). Significant associations were seen for all plasma biomarkers in late life with late-life dementia, with the largest association for NfL (hazard ratio per 1-SD increase, 1.92).

"The association of AD-specific biomarkers with dementia starts in midlife, whereas late-life measures of AD, neuronal injury, and astrogliosis biomarkers are all associated with dementia," the authors write.

Two authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Editorial

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Intensive BP Reduction Effective for Lowering All-Cause Dementia Risk

TUESDAY, April 29, 2025 -- An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and...

32 Percent of Dementia Attributed to Audiometric Hearing Loss

MONDAY, April 28, 2025 -- The population attributable fraction of dementia from any audiometric hearing loss is 32.0 percent, according to a study published online April 17 in...

Moderately Preterm Birth Tied to Long-Term Cognitive Problems

FRIDAY, April 25, 2025 -- Moderately preterm birth is associated with cognitive problems at ages 9 to 10 years, according to a study published online April 14 in JAMA Network...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.